Categories Health Care, Markets

Marinus Pharmaceuticals (MRNS) surges on positive data from Ganaxolone trial

Shares of Marinus Pharmaceuticals (MRNS) jumped after the pharma company reported positive data from the Phase 2 ganaxolone clinical trial in women with postpartum depression (PPD). The announcement excited the investors and sent the stock upwards by 18% in the pre-market trading session. However, the stock lost the initial momentum and opened up 10% when it started trading in today’s regular session.

Marinus stated that ganaxolone, its clinical stage drug, was safe and well-tolerated in all dose groups during the trial.  The company added that there were no serious adverse events reported and no discontinuations due to a treatment-related adverse event.

Based on the clinical results, Marinus plans to advance the studies into the next phase of development to evaluate ganaxolone IV and oral dose regimens. The company also expects to present the data from these studies in 1H19.

Postpartum depression is a mood disorder that affects about 15% of women within the first year following childbirth. Common symptoms include feelings of extreme sadness, hopelessness, suicidal ideation, anxiety and fatigue. So far there are no approved treatments for PPD, but the most common treatments are psychotherapy and antidepressants.

Last Tuesday, the Radnor, Pennsylvania-based pharma company, presented data from its ganaxolone Phase 2 clinical trial for the treatment of pediatric genetic epilepsies at the American Epilepsy Society (AES) Annual Meeting. Marinus stated that ganaxolone showed sustained, long-term effectiveness in treating children with CDD, a refractory form of pediatric epilepsy.

Proteostasis Therapeutics stock skyrockets on positive trial results

MRNS stock had dropped 25% in the past three months and 40% in the past one year. The stock closed down 2.64% at $5.17 on Friday.

Also Read:  CVS Health Corp. (CVS) Q2 2020 Earnings Call Transcript

 

We’re on Flipboard! Follow us to receive the latest stock market, earnings and financial news at your fingertips

Most Popular

Biocept (BIOC) revenue drops 23% in Q2; loss narrows

Biocept (NASDAQ: BIOC) reported a narrower loss in the second quarter of 2020. The company's revenue declined by 23% year-over-year to $917,000, hurt by the COVID-19 pandemic. BIOC stock slumped

Lyft rides home better-than-expected results in Q2

Lyft Inc (NASDAQ: LYFT) reported second-quarter financial results after the closing bell on Wednesday. The ride-hailing company reported a 61% dip in Q2 revenues to $339.3 million, narrowly beating Wall

Cisco Systems (CSCO) Q4 earnings drop but top expectations

https://www.youtube.com/watch?v=AFttiM-lTuY&t=138s Network gear maker Cisco Systems, Inc. (NASDAQ: CSCO) on Wednesday announced financial results for the fourth quarter of fiscal 2020, reporting a decline in earnings and revenues. However, the

Top